Sein Métastatique SAFIR02 Breast Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer. Paris, Saint-Cloud MARIE PAULE SABLIN
Gynécologie - Ovaires GREAT 1550-C081 Genomic BRCA and Extensive ovArian cancer Testing Paris, Saint-Cloud MANUEL RODRIGUES, MANUEL RODRIGUES
Sein métastatique triple négatif TOPOLOGY A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
VADS MIBI-THYR Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology. Saint-Cloud
Sein Métastatique MONDRIAN Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Sein métastatique triple négatif START A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recurrent (Unresectable) or Metastatic Breast Cancer Treated With Darolutamide or Capecitabine Saint-Cloud FLORENCE LEREBOURS
Hématologie Myélodysplasie QPL-MDS Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) Saint-Cloud SANDRA MALAK
Soins de support LE DECLIC-EPRI (IC 2019-06) DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI. Paris, Saint-Cloud EVELYNE RENAULT TESSIER
Sein métastatique triple négatif MS200647-0020/BREAST020 A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer Saint-Cloud FRANCOIS-CLEMENT BIDARD